HCW Biologics Inc. (HCWB) Dividend History

HCW Biologics Inc. (HCWB) is a biopharmaceutical company focused on developing immunotherapy treatments utilizing natural killer (NK) cell-based platforms. The company aims to address various unmet medical needs through innovative therapies that leverage the body's immune system to target and destroy cancer cells. HCW Biologics is involved in research and development efforts to advance its pipeline of biologic products with potential applications in oncology and other therapeutic areas.

2929 N Commerce Pkwy, Miramar, FL, 33025
Phone: 954-842-2024
Website: https://www.hcwbiologics.com

Dividend History

HCW Biologics Inc. currently does not pay dividends

Company News

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

HCW Biologics, a clinical-stage biopharmaceutical company, announced the pricing of a $5.0 million follow-on offering. The company plans to use the proceeds for funding preclinical and clinical development, business development, and general corporate purposes.

GlobeNewswire Inc.
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

HCW Biologics, a clinical-stage biopharmaceutical company, announced a $6.9 million registered direct offering and concurrent private placement. The company plans to use the proceeds to advance its immunotherapy drug discovery platforms and pipeline.

Benzinga
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

HCW Biologics, a clinical-stage biopharmaceutical company, announced a $6.9 million registered direct offering and concurrent private placement. The company plans to use the proceeds to develop new immunotherapeutic treatments.

GlobeNewswire Inc.
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

HCW Biologics has entered into a worldwide exclusive license agreement with WY Biotech to develop and commercialize one of HCW Biologics' product candidates. HCW Biologics will receive an upfront payment of $7 million and is eligible for additional milestone payments and royalties on future product sales.

GlobeNewswire Inc.
FDA Inspection Preparedness and Compliance Seminar: Information and for Tools Pharmaceutical, Biopharmaceutical, Biologics and Medical Device Professionals | ON-DEMAND

This article discusses a two-day seminar that aims to provide pharmaceutical, biopharmaceutical, biologics, and medical device professionals with the information and tools they need to prepare for and manage FDA inspections effectively.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 08:31:59 UTC